A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Summary

The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.

Timeline

Start

2021-04-13

Primary completion

2022-10-01

Completion

2023-04-26

Outcome

Met primary endpoint

registry analysis (superiority test); Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg; p <.001; LS Mean Difference -0.29 (95% CI -0.43 to -0.14); Mixed Models Analysis NCT04809220 ↗

Drugs

Indications